
    
      The drug being tested in this study is called Cabozantinib. Cabozantinib is being tested to
      treat advanced hepatocellular carcinoma in Japanese patients. This study will look at the
      efficacy and safety of Cabozantinib.

      The study will enroll 34 patients. Participants will be assigned to Cohort A (at least 17
      participants) or Cohort B (approximately 15 participants) and will receive the following
      treatment. Participants who have received prior sorafenib will enroll to Cohort A and
      participants who have not received prior sorafenib will enroll to Cohort B.

      - Cabozantinib 60 mg

      All participants will be asked to take one tablet of cabozantinib once daily in the fasted
      state (dose at least 2 hours after meal and no more food intake for 1 hour postdose)
      throughout the study.

      This multi-center trial will be conducted in Japan. The overall time to participate in this
      study is approximately at most 3 years. Participants will make multiple visits to the clinic
      during the treatment and posttreatment period, including a follow-up assessment after last
      dose of study drug.
    
  